Reconstituting Injectables at the Point-of-Care

Reconstituting Injectables  Reconstituting Injectables at the Point-of-Care • RJPC499K

  January 2022 • US$3,850



The inherent instability of biological drugs is a limitation that has a direct impact on the drug delivery sector. Therapeutic proteins must either be stored under special conditions or formulated to retain their efficacy from the time of manufacture until they are dispensed. Liquid protein drugs require refrigeration until dispensed. Alternatively, proteins can be formulated as powders (lyophilization) and must be reconstituted prior to injection. Historically, this was accomplished by including a disposable syringe and diluent vial for manual reconstitution. As the number of drugs developed for self-administration has grown, devices that integrate a reconstitution step with the injection step have gained traction. As biological drugs continue to grow in terms of therapeutics and total prescriptions, the impact of specialty devices will increase.

reconstituting Injectables




What You Will Learn

  • What is the impact of lyophilized injectable drugs on today’s therapeutic market, how are they packaged, and who markets them?
  • Who are the suppliers of integrated reconstitution devices, and what is their market impact?
  • What are the major factors driving the demand for integrated devices for injectable drug reconstitution?
  • What is the relative impact of integrated reconstitution systems to OEM or standalone reconstitution devices and how will this change by the end of the decade?
  • What are the essential design factors, material selection issues, technologies and market development issues for drug reconstitution systems and devices?
  • What is the role of integrated drug reconstitution systems on drug life cycle management?
  • What are the significant economic, technology, and regulatory factors affecting the market for injectable drugs and reconstitution systems in particular?


Reconstituting Injectables at the Point-of-Care – Summary of Contents 

Executive Summary

Reconstituting Injectables at the PoC

Drug Reconstitution Market Dynamics

Reconstitution – A Fact of Biological Drug Life

The Injectable Drug Ecosystem

Evolution in Device Design

Formulation Factors

Product Specific Device Development

Specialty Injection Device Demand Drivers

Chronic Conditions and Self-Administration

The Growth of Biologicals

Formulation and Dosing

Shifting Patient Demographics

Safety and Adherence

Device Design and Innovation

Competitive Landscape

Technology Market Drivers

Integrated Devices for POC Reconstitution

Dual Chamber Cartridges

Dual Chamber Injectors

Dual Chamber Syringes

Wearable  Automated Recon System

Device Assessments

Product-Specific Devices

Specialty Devices

OEM Devices

Dual Chamber Safety Syringe (Credence

Therapeutic Segments – Data & Forecasts

Hormone Replacement

Infectious Disease

Metabolic Conditions




Reproductive Health

Other Therapeutic Segments

Market Factors

Device Product Strategies

Device Economics

Product Branding

Direct-to-Consumer Marketing

Managed Care Trends

Company Profiles